APA

Johansson E. C., Hartz S., Kiri S. H., Kumar G. & Svedbom A. (20181226). Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK. : Journal of medical economics.

Chicago

Johansson Erin Colleen, Hartz Susanne, Kiri Sandeep Himatlal, Kumar Gayathri and Svedbom Axel. 20181226. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK. : Journal of medical economics.

Harvard

Johansson E. C., Hartz S., Kiri S. H., Kumar G. and Svedbom A. (20181226). Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK. : Journal of medical economics.

MLA

Johansson Erin Colleen, Hartz Susanne, Kiri Sandeep Himatlal, Kumar Gayathri and Svedbom Axel. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK. : Journal of medical economics. 20181226.